產品詳情
簡單介紹：
CCL-155 RPMI 8226 人多發性骨髓瘤細胞，ATCC 細胞|細胞系|細胞株|腫瘤細胞|細胞,細胞庫管理規范,提供 *優培養條件,
詳情介紹：
CCL-155 RPMI 8226 人多發性骨髓瘤細胞
ATCC® Number: CCL-155?
Designations: RPMI 8226
Isotype: lambda light chain
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens (human)
Morphology: lymphoblast
Source: Organ: peripheral blood
Disease: plasmacytoma; myeloma
Cell Type: B lymphocyte;
Cellular Products: immunoglobulin light chain
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: June, 1966
Applications: transfection host
Virus Susceptibility: Human poliovirus 1
Herpes simplex virus
Vaccinia virus
Vesicular stomatitis virus
Antigen Expression: HLA Aw19, B15, B37, Cw2; CD19 -; CD20 -; CD28 +; CD38 +; CD49e +
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 12
D13S317: 11
D16S539: 9
D5S818: 11,13
D7S820: 9,10
THO1: 8
TPOX: 8,11
vWA: 16,18
Cytogenetic Analysis: Unstable karyotype in triploid range of 68-70 chromosomes. Two large marker chromosomes with terminal centromeres.
Isoenzymes: G6PD, A
Age: 61 years
Gender: male
Comments: There is no evidence of heavy chain production (cytoplasmic or secreted).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(5) viable cells/ml.Do not allow the cell density to exceed 2 to 3 X 10(6) cells/ml.
Interval: Maintain cell density between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
purified DNA:ATCC CCL-155D
References: 1030: Matsuoka Y, et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125: 1246-1250, 1967. PubMed: 6042436
26017: Moore GE, Kitamura H. Cell line derived from patient with myeloma. N.Y. State J. Med. 68: 2054-2060, 1968. PubMed: 5243066
43268: Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375
ATCC® Number: CCL-155?
Designations: RPMI 8226
Isotype: lambda light chain
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens (human)
Morphology: lymphoblast
Source: Organ: peripheral blood
Disease: plasmacytoma; myeloma
Cell Type: B lymphocyte;
Cellular Products: immunoglobulin light chain
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: June, 1966
Applications: transfection host
Virus Susceptibility: Human poliovirus 1
Herpes simplex virus
Vaccinia virus
Vesicular stomatitis virus
Antigen Expression: HLA Aw19, B15, B37, Cw2; CD19 -; CD20 -; CD28 +; CD38 +; CD49e +
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 12
D13S317: 11
D16S539: 9
D5S818: 11,13
D7S820: 9,10
THO1: 8
TPOX: 8,11
vWA: 16,18
Cytogenetic Analysis: Unstable karyotype in triploid range of 68-70 chromosomes. Two large marker chromosomes with terminal centromeres.
Isoenzymes: G6PD, A
Age: 61 years
Gender: male
Comments: There is no evidence of heavy chain production (cytoplasmic or secreted).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(5) viable cells/ml.Do not allow the cell density to exceed 2 to 3 X 10(6) cells/ml.
Interval: Maintain cell density between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
purified DNA:ATCC CCL-155D
References: 1030: Matsuoka Y, et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125: 1246-1250, 1967. PubMed: 6042436
26017: Moore GE, Kitamura H. Cell line derived from patient with myeloma. N.Y. State J. Med. 68: 2054-2060, 1968. PubMed: 5243066
43268: Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375
